

Technical Data Sheet



InVivoSIM bispecific anti-human CD3 x CD20 (Glofitamab Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: SIMB0098
Clone: Glofitamab
Isotype: Human IgG1, κ
Recommended Isotype Control(s): RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Reported Applications: *in vivo* functional assays
in vitro functional assays
ELISA
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: ≤ 0.5 EU/mg (≤ 0.0005 EU/ μ g)
Determined by LAL assay
Purity: $\geq 95\%$
Determined by SDS-PAGE
Sterility: 0.2 μ m filtration
Production: Purified from cell culture supernatant in an animal-free facility
Purification: Protein A
RRID:
Molecular Weight: 150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This Glofitamab biosimilar antibody uses the same variable regions as the therapeutic antibody Glofitamab, making it ideal for research use. Glofitamab is a humanized bispecific IgG1 monoclonal antibody that simultaneously targets human CD3 on T cells and human CD20 on B cells. Its unique 2:1 configuration (two CD20-binding arms and one CD3-binding arm) enhances avidity for CD20-positive tumor cells while enabling potent T-cell engagement and cytotoxic activity. By bridging CD3 and CD20, Glofitamab promotes immunological synapse formation, T-cell activation, cytokine release, and selective killing of malignant B cells. Clinically, Glofitamab has demonstrated strong efficacy in relapsed or refractory B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL), and provides sustained tumor responses even in patients previously exposed to CAR-T therapy. This Glofitamab biosimilar is well suited for studying T-cell redirection, tumor cell killing, B-cell malignancy biology, and the mechanistic basis of IgG-like bispecific antibody therapeutics.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/simb0098?bxcs=9k1b3a#tab_references or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC